Stay updated on Safety Efficacy 50 mg NYX-783 QD vs. Placebo Clinical Trial
Sign up to get notified when there's something new on the Safety Efficacy 50 mg NYX-783 QD vs. Placebo Clinical Trial page.

Latest updates to the Safety Efficacy 50 mg NYX-783 QD vs. Placebo Clinical Trial page
- CheckyesterdayChange DetectedThe footer now identifies the site as revision v3.8.0 instead of v3.7.2. The study record page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedA sitewide notice about NIH’s website transition was added, and the footer revision changed from v3.7.1 to v3.7.2. The study record continues to display a 403 Forbidden error.SummaryDifference1%

- Check29 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check43 days agoChange DetectedThe study page now shows a 403 Forbidden error, replacing the detailed study content with a simple header. This blocks access to the study’s details, locations, and submission information.SummaryDifference16%

- Check50 days agoChange DetectedThe page now displays Revision: v3.7.0, signaling a new site build. This update is an administrative change that updates the revision label rather than content or functional elements.SummaryDifference0.1%

- Check64 days agoChange DetectedThe page revision identifier was updated from v3.6.5 to v3.6.6, indicating a software version update without describing any content changes.SummaryDifference0.0%

Stay in the know with updates to Safety Efficacy 50 mg NYX-783 QD vs. Placebo Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety Efficacy 50 mg NYX-783 QD vs. Placebo Clinical Trial page.